Pyrimidine salvage in Toxoplasma gondii as a target for new treatment
Frontiers in Cellular and Infection Microbiology · 2023
DOI: 10.3389/fcimb.2023.1320160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Hamza A A Elati und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom. Hauptthemen laut MEDLINE: Toxoplasma, Toxoplasmosis. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIGMS NIH HHS.
Abstract (Originalsprache)
Toxoplasmosis is a common protozoan infection that can have severe outcomes in the immunocompromised and during pregnancy, but treatment options are limited. Recently, nucleotide metabolism has received much attention as a target for new antiprotozoal agents and here we focus on pyrimidine salvage by Toxoplasma gondii as a drug target. Whereas uptake of [ 3 H]-cytidine and particularly [ 3 H]-thymidine was at most marginal, [ 3 H]-uracil and [ 3 H]-uridine were readily taken up. Kinetic analysis of uridine uptake was consistent with a single transporter with a K m of 3.3 ± 0.8 µM, which was inhibited by uracil with high affinity (K i = 1.15 ± 0.07 µM) but not by thymidine or 5-methyluridine, showing that the 5-Me group is incompatible with uptake by T. gondii . Conversely, [ 3 H]-uracil transport displayed a K m of 2.05 ± 0.40 µM, not significantly different from the uracil K i on uridine transport, and was inhibited by uridine with a K i of 2.44 ± 0.59 µM, also not significantly different from the experimental uridine K m . The reciprocal, complete inhibition, displaying Hill slopes of approximately -1, strongly suggest that uridine and uracil share a single transporter with similarly high affinity for both, and we designate it uridine/uracil transporter 1 (TgUUT1). While TgUUT1 excludes 5-methyl substitutions, the smaller 5F substitution was tolerated, as 5F-uracil inhibited uptake of [ 3 H]-uracil with a K i of 6.80 ± 2.12 µM ( P > 0.05 compared to uracil K m ). Indeed, we found that 5F-Uridine, 5F-uracil and 5F,2’-deoxyuridine were all potent antimetabolites against T. gondii with EC 50 values well below that of the current first line treatment, sulfadiazine. In vivo evaluation also showed that 5F-uracil and 5F,2’-deoxyuridine were similarly effective as sulfadiazine against acute toxoplasmosis. Our preliminary conclusion is that TgUUT1 mediates potential new anti-toxoplasmosis drugs with activity superior to the current treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
- Department of Pharmacology and Toxicology, Pharmacy College, University of Elmergib, Al Khums, Libya.
- Larner College of Medicine at The University of Vermont, Department of Microbiology and Molecular Genetics, Burlington, VT, United States.
- Wellcome Centre for Integrative Parasitology, University of Glasgow, Glasgow, United Kingdom.
Förderung
- Wellcome Trust
- NIGMS NIH HHS
Zitieren
APA
Elati, H. A. A., Goerner, A. L., Martorelli Di Genova, B., Sheiner, L., & de Koning, H. P. (2023). Pyrimidine salvage in Toxoplasma gondii as a target for new treatment. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1320160
Vancouver
Elati HAA, Goerner AL, Martorelli Di Genova B, Sheiner L, de Koning HP. Pyrimidine salvage in Toxoplasma gondii as a target for new treatment. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1320160
BibTeX
@article{Elati2023,
author = {Elati, Hamza A A and Goerner, Amber L and Martorelli Di Genova, Bruno and Sheiner, Lilach and de Koning, Harry P},
title = {Pyrimidine salvage in Toxoplasma gondii as a target for new treatment},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
doi = {10.3389/fcimb.2023.1320160}
}
EUVIMED